• Vetiranary Medicine
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA seeks input on Web ads about drugs, medical products

September 21, 2009

Washington -- The U.S. Food and Drug Administration (FDA) is asking health-care providers, veterinarians included, to voice their opinions on the regulation of medical products and prescription-drug promotions on the Internet and social networking sites.

Washington

-- The U.S. Food and Drug Administration (FDA) is asking health-care providers, veterinarians included, to voice their opinions on the regulation of medical products and prescription drug promotions on the Internet and social networking sites.

Current regulations for medical products and prescription advertising don’t define what constitutes an advertisement, according to the FDA, but do state that ads must include “true statements” about the product, side effects and contraindications.

The question for the FDA is where its place should be in regulating information on the Internet about certain products and drugs, taking into consideration the fact that companies sometimes invite customers to share their reactions on sites like YouTube.

“There are no regulations that specifically address Internet promotion separately from other types of promotion … nor are there any regulations that prohibit the use of certain types of media to promote drugs and medical devices,” says the FDA.

Advertisement

Specific questions the FDA expects to address include identifying what online communications manufacturers, distributors and packers can be held accountable for and how regulatory requirements can be met with limited space and tools for real-time communications like microblogs (such as Twitter) and mobile technology.

FDA’s Center for Drug Evaluation and Research is working with the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health and the Center for Veterinary Medicine to get public comment. Input from patients, consumers, health-care providers and the regulated health-care industry will guide policy-making decisions on Internet and social media marketing of human and animal prescription drugs and devices, says the FDA.

A public hearing is set for Nov. 12 and 13 from 8 a.m. to 5 p.m. at the National Transportation Safety Board Conference Center, 429 L’Enfant Plaza, SW, Washington, D.C. 20594. Participants must register for the hearing by Oct. 9, but written and electronic comments will be accepted until Feb. 28, 2010.

Click hereto view the full hearing notice.

Related Content:

RegulatoryBreaking News
USDA aims to strengthen handling regulations for exotic animals in exhibition
USDA aims to strengthen handling regulations for exotic animals in exhibition
Veterinarian kills 2 police officers in Mississippi
Veterinarian kills 2 police officers in Mississippi
FDA conditionally approves Panoquell-CA1 for acute onset of canine pancreatitis
FDA conditionally approves Panoquell-CA1 for acute onset of canine pancreatitis

Advertisement

Latest News

Spectrum of care: protocols to support pet owners’ budgets

How to support women while still running a successful business

The Vets expands to Raleigh, NC

Two pups find their forever homes while at Fetch Charlotte

View More Latest News
Advertisement